The first generic filer gets 180 days of exclusivity under the Hatch-Waxman Act to encourage patent challenges and lower drug prices. But loopholes let some companies delay launches, blocking competition and keeping prices high.
Providers face growing hurdles securing approval for generic medications due to insurer restrictions. Learn how to navigate prior authorization requirements, avoid common denials, and speed up approvals with proven strategies.